Dipti M Karamchandani
Overview
Explore the profile of Dipti M Karamchandani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karamchandani D, Gonzalez R, Lee H, Westerhoff M, Cox B, Pai R
Histopathology
. 2025 Jan;
PMID: 39875182
Aims: The current American Joint Committee on Cancer (AJCC) staging manual and the College of American Pathologists (CAP) colorectal carcinoma (CRC) protocol specify use of a four-tiered grading system (i.e....
2.
Chi Z, Peng L, Karamchandani D, Xu J
Ann Diagn Pathol
. 2024 Nov;
74:152394.
PMID: 39549525
Programmed cell death-ligand 1 (PD-L1) clone 22C3 is the only Food and Drug Administration-approved companion diagnostic test for pembrolizumab for the treatment of esophageal squamous cell carcinoma (ESCC). However, prior...
3.
Sica E, Shore K, Yang L, Phelps K, Hammer S, Gopal P, et al.
Diagn Pathol
. 2024 Sep;
19(1):129.
PMID: 39334193
Background: Distinguishing reactive atypia from dysplasia in cholecystectomy specimens can be histologically challenging. The aim of this study was to evaluate the utility of IMP3, p53, and S100P immunostains in...
4.
Liu Y, Esnakula A, Jain S, Lin J, Panarelli N, Pyatibrat S, et al.
Histopathology
. 2024 Sep;
86(2):285-293.
PMID: 39267205
Aims: Neuroendocrine tumours (NETs) occurring in the extrahepatic biliary system are exceedingly rare. While NETs typically manifest as mass lesions, the occurrence of microscopic neuroendocrine cell proliferation without a distinct...
5.
Tomm N, Szczepanski J, Fang J, Choi W, Xue Y, Setia N, et al.
Hum Pathol
. 2024 May;
148:60-65.
PMID: 38734079
Colitis is a common manifestation of immune checkpoint inhibitor (ICI) toxicity and can present with varied histologic patterns of inflammation, some of which have been shown to be associated with...
6.
Chi Z, Xu J, Karamchandani D, Peng L
Ann Diagn Pathol
. 2024 Apr;
71:152304.
PMID: 38614035
Introduction: Differentiating pancreatic serous cystadenoma (SCA) from well-differentiated neuroendocrine tumors (WDNETs) based on histomorphology is critical yet challenging, particularly in small biopsy samples. Our study aimed to examine the expression...
7.
Choe A, Kasales C, Mack J, Al-Nuaimi M, Karamchandani D
J Breast Imaging
. 2024 Feb;
4(1):48-55.
PMID: 38422411
Breast MRI provides high sensitivity but modest positive predictive value for identifying breast cancers, with approximately 75% of MRI-guided biopsies returning benign pathologies. Fibrocystic change (FCC) is a descriptive term...
8.
Vyas M, Karamchandani D
J Clin Pathol
. 2024 Feb;
77(3):169-176.
PMID: 38373784
An astute macroscopic examination, coupled with correlating the gross findings with clinical indication and operative notes along with judicious, yet all pertinent sectioning for pathological examination is crucial for an...
9.
Varma M, Collins L, Chetty R, Karamchandani D, Talia K, Dormer J, et al.
J Clin Pathol
. 2023 Dec;
77(3):164-168.
PMID: 38053286
Meticulous macroscopic examination of specimens and tissue sampling are crucial for accurate histopathology reporting. However, macroscopy has generally received less attention than microscopy and may be delegated to relatively inexperienced...
10.
Mitchell J, Karamchandani D
Surg Pathol Clin
. 2023 Oct;
16(4):703-718.
PMID: 37863561
Immune checkpoint inhibitors have revolutionized the management of many advanced cancers by producing robust remissions. They mostly target two immune regulatory pathways: cytotoxic T lymphocyte antigen-4 and programmed death-1 or...